Latest News

  • NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Read More
  • Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference Read More
  • Alkermes Announces Updates to Executive Leadership Team Read More
  • FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831 Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

COVID-19

Response to Current Events
COVID-19 Read Our Response